REPL Replimune Group, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

REPL [NASD]

Replimune Group, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.52	Insider Own	12.80%	Shs Outstand	38.82M	Perf Week	-0.05%
Market Cap	882.90M	Forward P/E	-	EPS next Y	-2.16	Insider Trans	-4.54%	Shs Float	34.46M	Perf Month	4.38%
Income	-52.60M	PEG	-	EPS next Q	-0.46	Inst Own	80.00%	Short Float	1.62%	Perf Quarter	75.38%
Sales	-	P/S	-	EPS this Y	-15.60%	Inst Trans	-1.19%	Short Ratio	2.72	Perf Half Y	34.57%
Book/sh	4.73	P/B	4.68	EPS next Y	-11.90%	ROA	-27.00%	Target Price	29.43	Perf Year	68.70%
Cash/sh	4.23	P/C	5.24	EPS next 5Y	-	ROE	-33.30%	52W Range	8.58 - 26.22	Perf YTD	54.36%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-15.52%	Beta	-
Dividend %	-	Quick Ratio	14.70	Sales past 5Y	-	Gross Margin	-	52W Low	158.16%	ATR	1.96
Employees	122	Current Ratio	14.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.75	Volatility	7.36% 8.37%
Optionable	No	Debt/Eq	0.20	EPS Q/Q	-92.40%	Profit Margin	-	Rel Volume	0.90	Prev Close	22.15
Shortable	Yes	LT Debt/Eq	0.19	Earnings	-	Payout	-	Avg Volume	204.76K	Price	22.15
Recom	1.90	SMA20	-1.28%	SMA50	6.36%	SMA200	39.57%	Volume	0	Change	0.00%

Jul-01-20

Downgrade

H.C. Wainwright

Buy → Neutral

$25

May-05-20

Initiated

Barclays

Overweight

$21

Sep-04-19

Initiated

ROTH Capital

Buy

$20

Jul-23-19

Initiated

Chardan Capital Markets

Buy

$28

Jul-12-19

Upgrade

JP Morgan

Neutral → Overweight

$27 → $26

Jul-08-19

Initiated

H.C. Wainwright

Buy

$26

Apr-25-19

Initiated

Wedbush

Outperform

$24

Jan-23-19

Downgrade

JP Morgan

Overweight → Neutral

Aug-14-18

Initiated

Leerink Partners

Outperform

$25

Aug-14-18

Initiated

JP Morgan

Overweight

$26

Jun-22-20 02:27PM	Replimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure Insider Monkey
Jun-17-20 08:00AM	Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
Jun-11-20 08:47AM	Replimune (REPL) Looks Good: Stock Adds 5.8% in Session Zacks
Jun-08-20 11:21PM	Replimune Announces Pricing of Upsized Public Offering GlobeNewswire
04:16PM	Replimune Announces Proposed Public Offering GlobeNewswire
Jun-03-20 07:15AM	Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update GlobeNewswire
07:00AM	Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimunes Ongoing Registration-Directed Clinical Trials with RP1 GlobeNewswire
Apr-30-20 06:00AM	Replimune to Provide Data Update on June 3, 2020 GlobeNewswire +20.84%
Apr-02-20 07:00AM	Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors GlobeNewswire
Feb-13-20 07:00AM	Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Feb-06-20 08:00AM	Replimune to Present at Two Upcoming Investor Conferences GlobeNewswire -5.08%
Jan-13-20 07:00AM	Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones GlobeNewswire
Jan-09-20 07:00AM	Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization GlobeNewswire
Jan-07-20 08:00AM	Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference GlobeNewswire
Dec-23-19 02:56PM	Replimune Group, Inc. (NASDAQ:REPL): Are Hedge Funds Right About This Stock? Insider Monkey
Dec-09-19 08:00AM	Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer GlobeNewswire
Nov-26-19 08:00AM	Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference GlobeNewswire
Nov-22-19 12:13PM	Largest Insider Trades of the Week GuruFocus.com
Nov-14-19 06:22AM	Replimune Announces Pricing of Public Offering GlobeNewswire
Nov-12-19 04:06PM	Replimune Announces Proposed Public Offering GlobeNewswire
Nov-11-19 08:00AM	Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Nov-08-19 07:30AM	Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC) GlobeNewswire
Oct-31-19 04:00PM	Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire
02:19PM	Is Replimune Group, Inc. (REPL) A Good Stock To Buy? Insider Monkey
Oct-24-19 08:00AM	Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients GlobeNewswire
Oct-15-19 07:00AM	Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma GlobeNewswire +15.02%
Oct-02-19 08:00AM	Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -5.77%
Oct-01-19 08:00AM	Replimune to Present at Chardans 3rd Annual Genetic Medicines Conference GlobeNewswire -5.25%
Sep-13-19 04:39AM	2 Downtrodden Small Biotechs That Are Showing Signs of Life TheStreet.com
Aug-14-19 08:00AM	Replimune Reports First Fiscal Quarter Financial Results and Provides Corporate Update GlobeNewswire
Aug-06-19 08:00AM	Replimune to Present at 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire -5.53%
Jul-19-19 09:16AM	Imagine Owning Replimune Group (NASDAQ:REPL) And Wondering If The 17% Share Price Slide Is Justified Simply Wall St.
Jun-28-19 08:00AM	Replimune Reports Fourth Fiscal Quarter and Year 2019 Financial Results and Provides Corporate Update GlobeNewswire +6.15%
Jun-01-19 09:00AM	Replimune Announces Initiation of the Phase 2 Portion of its Ongoing Phase 1/2 Clinical Trial of RP1 as Monotherapy and in Combination with Nivolumab GlobeNewswire
May-30-19 08:00AM	Replimune to Present at Upcoming Investor Conferences GlobeNewswire
May-16-19 07:00AM	Replimune Announces Poster Presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire +5.80%
Apr-25-19 02:23PM	Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation Benzinga +6.65%
Apr-01-19 07:00AM	Replimune Announces Presentation at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Feb-14-19 08:00AM	Replimune Reports Financial Results for the Third Fiscal Quarter, Ended December 31, and Provides Development and Corporate Update GlobeNewswire
Feb-07-19 08:00AM	Replimune to Present at Two Upcoming Investor Conferences GlobeNewswire
Jan-04-19 12:33PM	How Much Are Replimune Group, Inc. (NASDAQ:REPL) Insiders Spending On Buying Shares? Simply Wall St.
Jan-03-19 08:00AM	Replimune Highlights Company Progress and Expected 2019 Milestones Ahead of Presentation at the 37th Annual JPMorgan Healthcare Conference GlobeNewswire
Dec-20-18 08:00AM	Replimune to Present at the 37th Annual J.P.Morgan Healthcare Conference GlobeNewswire
Dec-08-18 06:19PM	RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
Dec-05-18 08:00AM	Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-14-18 08:38AM	Bain Capital Life Sciences Investors, LLC Buys Replimune Group Inc GuruFocus.com
08:00AM	Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update GlobeNewswire
Sep-26-18 08:00AM	Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology GlobeNewswire
Sep-06-18 04:01PM	Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1 GlobeNewswire
Aug-30-18 08:00AM	Replimune Reports Financial Results for the First Fiscal Quarter, Ended June 30, and Provides Development and Corporate Update GlobeNewswire -9.20%
Aug-14-18 02:49PM	BMO Sees A Low-Risk Biotech Buy In Replimune Benzinga
Jul-24-18 07:44AM	[$$] Gormley's Take: Public Markets' Embrace of Health Care Extends Beyond Biotech The Wall Street Journal

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coffin Robert	President & Chief R&D Officer	Jul 09	Sale	22.13	169,750	3,757,295	2,024,118	Jul 10 09:00 PM
Coffin Robert	Pres & Chief Res & Dev Officer	Feb 20	Sale	17.04	24,250	413,220	2,193,868	Feb 24 04:02 PM
Coffin Robert	Pres & Chief Res & Dev Officer	Feb 12	Sale	17.04	48,500	826,198	2,218,118	Feb 14 04:00 PM
Esposito Pamela	Chief Business Officer	Dec 20	Option Exercise	1.75	25,700	44,975	112,700	Dec 23 04:32 PM
Kaufman Howard	Chief Medical Officer	Nov 26	Option Exercise	3.30	58,067	191,621	58,067	Dec 19 04:02 PM
Rhodes Jason P	Director	Nov 18	Buy	13.61	1,100,000	14,971,000	1,100,000	Nov 20 05:50 PM
Omega Fund IV, L.P.	10% Owner	Nov 18	Buy	13.61	220,000	2,994,200	5,328,939	Nov 20 12:36 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience